Clinical TrialSep 29, 2026, 06:36 AM
Alzamend Neuro Investigator Presents Phase 1/2A Lithium Trial Data
AI Summary
Alzamend Neuro, Inc. announced that its Phase 1/2A clinical trial principal investigator presented findings at the ISMRT Conference. The presentation detailed the pharmacokinetics of AL001, a novel organic lithium salt, using 7 Tesla MRI to quantify brain lithium concentrations. While trends suggested slightly higher levels and AUC with AL001 compared to inorganic lithium carbonate, these differences were not statistically significant due to the small sample size. The observed trends will be further investigated in patient cohorts with various neurological and psychiatric conditions.
Key Highlights
- Alzamend Neuro's Phase 1/2A clinical trial principal investigator presented findings at the ISMRT Conference.
- The presentation focused on the pharmacokinetics of AL001, a novel organic lithium salt, compared to inorganic lithium carbonate.
- 7 Tesla MRI was used to quantify lithium concentration in the brain, showing a trend for slightly higher levels with AL001.
- PK analysis indicated a trend for slightly higher AUC with AL001 compared to Li2CO3, though not statistically significant.
- The observed trends in healthy cohorts will be tested in subsequent patient cohorts for bipolar, major depression, Alzheimer, and PTSD.
Price Impact
More from ALZN